Phase 2 Study

Edit

Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases (Form 6-K) (Immutep Ltd)

Public Technologies 20 Mar 2026

Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases •.

Edit

Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases

Nasdaq Globe Newswire 19 Mar 2026

IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune ...

Edit

Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases (Immutep Ltd)

Public Technologies 19 Mar 2026

) Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases.

Edit

Company well-funded to complete DReAMzz Phase 2 study while preserving capital for optimized Phase 3 program (Form 8-K) (Incannex Healthcare Inc)

Public Technologies 18 Mar 2026

Company well-funded to complete DReAMzz Phase 2 study while preserving capital for optimized Phase 3 program ... to fund the Company's DReAMzz Phase 2 crossover dose-optimization study for IHL-42X.

Edit

MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control (Metavia Inc)

Public Technologies 18 Mar 2026

In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.

Edit

MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control

PR Newswire 18 Mar 2026

16-Week Study to Evaluate One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults ... In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.

Edit

CinDome Pharma Announces Completion of Enrollment in the envisionGI Phase 2 Study of Deudomperidone (CIN-102) ...

The Galveston Daily News 17 Mar 2026

CINCINNATI--(BUSINESS WIRE)--Mar 17, 2026-- ....

Edit

MedPharm Welcomes Palvella Therapeutics’ Positive Topline Results from its Phase 3 study of QTORIN™ Rapamycin in Microcystic Lymphatic Malformations

Pharmiweb 17 Mar 2026

PVLA), recently announced positive topline results from its Phase 3 SELVA study of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), an investigational therapy under development for the ...

Edit

YolTech Therapeutics Receives FDA Clearance to Initiate Phase 2/3 Study of In Vivo Gene-Editing Therapy ...

The Milton Standard Journal 14 Mar 2026

SHANGHAI--(BUSINESS WIRE)--Mar 14, 2026-- ....

Edit

YolTech Therapeutics Receives FDA Clearance to Initiate Phase 2/3 Study of In Vivo Gene-Editing Therapy YOLT-202 in Alpha-1 Antitrypsin Deficiency (AATD)

Pharmiweb 14 Mar 2026

The FDA approval enables the initiation of an open-label, single-dose expansion Phase 2/3 clinical study to evaluate the efficacy and safety of YOLT-202 in adult patients with Alpha-1 Antitrypsin Deficiency (AATD).

Edit

Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series ...

Nasdaq Globe Newswire 11 Mar 2026

The financing will enable the company to complete two Phase 2 trials with VIM0423 for isolated dystonia and Parkinson’s disease. The company expects to initiate a Phase 2 ...

Edit

Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of

Hastings Tribune 11 Mar 2026

New $40 million raise brings Series A total to $100M, ...

Edit

ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives

Caledonian Record 10 Mar 2026

Webcast and conference call to be held today, Tuesday March 10 at 9.30 a.m. AEDT (Monday March 9 at 6.30 p.m. EDT). Investors can register at the following link. https.//s1.c-conf.com/diamondpass/10053620-ju7y6t.html ....

Edit

Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be

Hastings Tribune 10 Mar 2026

SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Connect ...

Edit

Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in ...

Nasdaq Globe Newswire 10 Mar 2026

CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on transforming ...

Podcasts:

Latest News for: phase 2 study

Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases (Form 6-K) (Immutep Ltd)

Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases

Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases (Immutep Ltd)

Company well-funded to complete DReAMzz Phase 2 study while preserving capital for optimized Phase 3 program (Form 8-K) (Incannex Healthcare Inc)

MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control (Metavia Inc)

MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control

CinDome Pharma Announces Completion of Enrollment in the envisionGI Phase 2 Study of Deudomperidone (CIN-102) ...

MedPharm Welcomes Palvella Therapeutics’ Positive Topline Results from its Phase 3 study of QTORIN™ Rapamycin in Microcystic Lymphatic Malformations

YolTech Therapeutics Receives FDA Clearance to Initiate Phase 2/3 Study of In Vivo Gene-Editing Therapy ...

YolTech Therapeutics Receives FDA Clearance to Initiate Phase 2/3 Study of In Vivo Gene-Editing Therapy YOLT-202 in Alpha-1 Antitrypsin Deficiency (AATD)

Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series ...

Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of

ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives

Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be

Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in ...

Article Search

EXPLORE WN.com